NCT01580878已完成1 期
A Double-Blind, Randomized, Parallel-Group, Vehicle-Controlled, Multicenter Study to Evaluate the Safety and Bioequivalence of a Generic Butenafine Hydrochloride Cream, 1% and Reference Listed Lotrimin Ultra® (Butenafine Hydrochloride Cream, 1%) and Compare Both Active Treatments to a Vehicle Control in the Treatment of Interdigital Tinea Pedis.
适应症
干预措施
相关药物
试验速览
- 阶段
- 1 期
- 状态
- 已完成
- 入组人数
- 707
- 主要终点
- Therapeutic Cure
研究概览
简要总结
The primary objective of this study is to determine the comparability of the safety and efficacy of a generic Butenafine Hydrochloride Cream, 1% (test product) and Lotrimin Ultra® (the reference listed drug) in subjects with interdigital tinea pedis. It will also be determined whether the efficacy of each of the two active treatments is superior to that of the vehicle cream (placebo).
研究设计
- 研究类型
- Interventional
- 分配方式
- Randomized
- 干预模型
- Parallel
- 主要目的
- Treatment
- 盲法
- Double (Participant, Investigator)
入排标准
- 年龄范围
- 18 Years 至 —（Adult, Older Adult）
- 性别
- All
- 接受健康志愿者
- 否
入选标准
- •Willing & able to provide & understand written informed consent
- •Healthy male or non-pregnant, non-lactating female at least 18 years of age and older
- •Clinical diagnosis of tinea pedis with lesions localized to the interdigital spaces or that is predominantly interdigital but may extend to other areas
- •Tinea pedis provisionally confirmed at baseline by positive potassium hydroxide (KOH)wet mount preparation showing segmented fungal hyphae
- •Has sum of the clinical signs and symptoms scores of the target lesion of at least 4, including a minimum score of 2 for erythema & a minimum score of 2 for scaling or pruritus
- •Currently in general good health with no clinically significant disease
- •Willing and able to understand and comply with study requirements
- •Women of childbearing potential must have a negative urine pregnancy test and be willing to use an acceptable form of birth control during study
排除标准
- •Females who are pregnant, breastfeeding, planning a pregnancy, or do not agree to use an acceptable form of birth control during the study
- •Confluent, diffuse moccasin-type tinea pedis of the entire plantar surface
- •Presence of any other infection of the foot or other disease that might confound treatment evaluation
- •History of dermatophyte infections unresponsive to antifungal drugs
- •Known hypersensitivity to Butenafine Hydrochloride or any component of the study medications
- •Use of antipruritics, topical systemic corticosteroid, antibiotic or antifungal therapy, oral terbinafine or itraconazole, or immunosuppressive medication or radiation therapy more recently than indicated washout period
- •Current oral, vaginal, or mucocutaneous candidiasis
- •Current bacterial skin infection, secondary cellulitis, lymphangitis, or pyoderma
- •Presence of current conditions that require systemic antimicrobial or antifungal therapy
- •Uncontrolled diabetes mellitus, peripheral vascular disease, chronic venous stasis, or other significant condition
- •Current severe onychomycosis
- •Any clinically significant condition or situation, other than condition being studied, that would interfere with the study evaluations or participation
- •Use of any investigational drugs or device within 30 days of signing Informed Consent Form (ICF)
- •Current participation in any other clinical study
- •Consumes excessive amounts of alcohol, abuses drugs, or has any condition that would compromise compliance
- •Previous participation in this study
- •Subjects with past history of tinea pedis with lack of response to antifungal therapy
- •Subjects who in Investigator's opinion would be non-compliant
- •Employees or direct relatives of an employee of the study center or Investigator
研究组 & 干预措施
Butenafine Hydrochloride Cream, 1%
Experimental
Butenafine Hydrochloride Cream, 1% (Taro Pharmaceuticals, Inc.)
干预措施: Butenafine Hydrochloride Cream, 1% (Drug)
Lotrimin Ultra®
Active Comparator
Lotrimin Ultra® (Butenafine Hydrochloride Cream, 1%) (Schering Plough HealthCare Products Inc.)
干预措施: Lotrimin Ultra® (Drug)
Butenafine Vehicle
Placebo Comparator
Butenafine Cream vehicle (Taro Pharmaceuticals Inc.)
干预措施: Butenafine Vehicle (Drug)
结局指标
主要结局
Therapeutic Cure
时间窗: 42 days
Subjects with both clinical cure and mycologic cure are considered therapeutic cures.
次要结局
未报告次要终点
研究者
相似试验
已完成
1 期
A Study to Evaluate the Safety and Bioequivalence of Mupirocin Calcium Cream, 2% and Bactroban® Cream and Compare Both to a Vehicle in Treatment of Secondarily Infected Traumatic Skin Lesions.Secondarily Infected Traumatic Skin LesionsNCT01876550Taro Pharmaceuticals USA1,902
已完成
3 期
Study To Evaluate The Efficacy And Safety Of Actikerall® Solution In Patients With Grade I-II Actinic KeratosesActinic KeratosisNCT02289768Almirall, S.A.166
已完成
2 期
Safety and Efficacy Study of Topically Applied DS107 Cream in Mild to Moderate Atopic Dermatitis Patients (AD)Atopic DermatitisNCT02925793DS Biopharma327
已完成
2 期
Study of TS-022 in Adult Patients With Atopic Dermatitis With Pruritus (POC)Atopic DermatitisNCT00914186Taisho Pharmaceutical R&D Inc.122
已完成
2 期
A Randomized, Vehicle-Controlled Study of 2 Concentrations of A-101 for the Treatment of Seborrheic KeratosisSeborrheic KeratosisNCT03148691Aclaris Therapeutics, Inc.253